Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - octreotide, quantity: 50 microgram - injection, solution - excipient ingredients: mannitol; glycine; water for injections; dilute hydrochloric acid - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). octreotide is not an antitumour therapy and is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - octreotide, quantity: 500 microgram - injection, solution - excipient ingredients: glycine; mannitol; dilute hydrochloric acid; water for injections - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). octreotide is not an antitumour therapy and is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - octreotide, quantity: 100 microgram - injection, solution - excipient ingredients: glycine; dilute hydrochloric acid; mannitol; water for injections - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). octreotide is not an antitumour therapy and is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide 50 ug in 1 ml - octreotide acetate injection is indicated to reduce blood levels of growth hormone (gh) and insulin growth factor-1 (igf-1; somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of gh and igf-1 (somatomedin c) levels (see dosage and administration) . in patients with acromegaly, octreotide acetate injection reduces gh to within normal ranges in 50% of patients and reduces igf-1 (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of gh and igf-1 (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials p

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide 50 ug in 1 ml - octreotide acetate injection is indicated to reduce blood levels of growth hormone (gh) and insulin growth factor-1 (igf-1; somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of gh and igf-1 (somatomedin c) levels (see dosage and administration) . in patients with acromegaly, octreotide acetate injection reduces gh to within normal ranges in 50% of patients and reduces igf-1 (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of gh and igf-1 (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trial

United States - English - NLM (National Library of Medicine)

sandoz inc - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide 200 ug in 1 ml - octreotide acetate is indicated to reduce blood levels of growth hormone and igf-i (somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of growth hormone and igf-i (somatomedin c) levels (see dosage and administration ). in patients with acromegaly, octreotide acetate reduces growth hormone to within normal ranges in 50% of patients and reduces igf-i (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate to reduce blood levels of growth hormone and igf-i (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide a

United States - English - NLM (National Library of Medicine)

mylan institutional llc - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide 50 ug in 1 ml - octreotide acetate injection is indicated to reduce blood levels of growth hormone (gh) and insulin growth factor-1 (igf-1; somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of gh and igf-1 (somatomedin c) levels (see dosage and administration). in patients with acromegaly, octreotide acetate injection reduces gh to within normal ranges in 50% of patients and reduces igf-1 (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of gh and igf-1 (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials pe

United States - English - NLM (National Library of Medicine)

wockhardt limited - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide 50 ug in 1 ml - octreotide acetate injection is indicated to reduce blood levels of growth hormone and igf-i (somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of growth hormone and igf-i (somatomedin c) levels (see dosage and administration). in patients with acromegaly, octreotide acetate reduces growth hormone to within normal ranges in 50% of patients and reduces igf-i (somatomedin c) to within normal ranges in 50%-60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate to reduce blood levels of growth hormone and igf-i (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octre

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide 50 ug in 1 ml - octreotide acetate injection is indicated to reduce blood levels of growth hormone and igf-i (somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of growth hormone and igf-i (somatomedin c) levels (see dosage and administration). in patients with acromegaly, octreotide acetate reduces growth hormone to within normal ranges in 50% of patients and reduces igf-i (somatomedin c) to within normal ranges in 50%-60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate to reduce blood levels of growth hormone and igf-i (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octre

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - octreotide, quantity: 20 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of th